Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act (117th Congress); FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of PREVENT Pandemics Act in Consolidated Appropriations Act, 2023 (PL 117-328).
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Duration: January 25, 2019
to
July 31, 2023
General Issues: Health Issues , Budget/Appropriations , Homeland Security , Disaster Planning/Emergencies
Spending: about $970,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Ryan Welch Legislative Director, Senator Richard Shelby; Legislative Assistant,
Senator Richard Shelby; Legislative Correspondent, Senator Richard
Shelby.
Legislative Director, Senator Richard Shelby
Legislative Assistant, Senator Richard Shelby
Legislative Correspondent, Senator Richard Shelby
Libby Greer Chief of Staff, Rep. Allen Boyd
Derrick White Deputy Press Secretary, Senator Orrin Hatch
Deputy Communications Director, Senator Orrin
Jeff Sadosky Communications Director, Senator Rob Portman, Communications
Director, Senator Kay Bailey Hutchison, Deputy Press Secretary, Senator
Mike DeWine
Jeffrey Sadosky Communications Director, Senator Rob Portman
Communications Director, Senator Kay Bailey Hutchison
Deputy Press Secretary, Senator Mike DeWine
Rick Murphy Chief of Staff, Senator Kelly Ayotte, April 14 - Jan. 17
Francesca McCrary Legislative Assistant, Rep. Elijah Cummings (2016-2017); Professional Staff, House Oversight & Reform Committee (2016)
Cindy Brown Chief of Staff, Rep. Ron Kind (2003-2009); Legislative Director, Rep. Ron Kind (1999-2002)
Rachel Miller Legislative Assistant, Sen. Dianne Feinstein (2003-2007); Legislative Assistant, Rep. Eliot Engel (2000-2003)
Michael Williams Legislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Brian Jones (2019); Legislative Correspondent, Sen. Brian Jones (2018-2019)
Arthur Sidney LD & Chief Counsel, Rep. Jackson Lee (2008-2009); Chief of staff and chief counsel, Rep. Johnson (2009-2020)
Zach Williams n/a
Ed Reno III n/a
Edward Reno III n/a
Jay Driscoll n/a
Zachary Williams n/a
Kristina Dunklin n/a
Edward Reno III n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
3rd Quarter, 2023
Forbes-Tate terminated an engagement in which they represented Emergent Biosolutions on Oct. 17, 2023.
Original Filing: 301503136.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, Further Extending Government Funding Act (PL 117-70); Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act (117th Congress); FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of PREVENT Pandemics Act in Consolidated Appropriations Act, 2023 (PL 117-328).
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 - State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress); H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (PL 117-328) and FY24 appropriations bills; Further Extending Government Funding Act (PL 117-70); Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on July 16, 2023.
Original Filing: 301477167.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on April 17, 2023.
Original Filing: 301453049.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; FY 2024 National Defense Authorization Act - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0 (117th Congress); H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022 (117th Congress); Issues related to the implementation of S. 3799 - PREVENT Pandemics Act in H.R. 2617 - Consolidated Appropriations Act, 2023.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0 (117th Congress); H.R. 2379 -State Opioid Response Grant Authorization Act of 2021 (117th Congress); H.R 2366/S.1457 - Stop Fentanyl Act (117th Congress), H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 (117th Congress); Issues related to the development, manufacture, and distribution of coronavirus vaccines; FY23 Omnibus appropriations bill (P.L. 117-328) and FY24 appropriations bills, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on Jan. 15, 2023.
Original Filing: 301427788.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0; H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022; S. 3799 - PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose; Issues regarding funding of the Strategic National Stockpile.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on Oct. 17, 2022.
Original Filing: 301406301.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0; H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022; S. 3799 - PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on July 16, 2022.
Original Filing: 301381687.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act; H.R.7900 - National Defense Authorization Act for Fiscal Year 2023 - provisions related to biological and chemical defense and access to naloxone; Issues related to H.R. 7681 - Preventing Overdoses and Saving Lives Act 2.0; H.R. 7666 - Restoring Hope for Mental Health and Well-Being Act of 2022; S. 3799 - PREVENT Pandemics Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987/H.R. 4341 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Appropriations funding for FY23 related to medical countermeasures and opioid overdose.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on April 15, 2022.
Original Filing: 301357300.xml
Lobbying Issues
Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on Jan. 17, 2022.
Original Filing: 301323904.xml
Lobbying Issues
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines; Issues related to the development, manufacture, and distribution of coronavirus vaccines; Outreach regarding H.R. 3263 - DHS Medical Countermeasures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone; Appropriations funding for Fiscal Year 2022, HR 6119 - Further Extending Government Funding Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on Oct. 16, 2021.
Original Filing: 301300355.xml
Lobbying Issues
H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; H.R 2366/S.1457 - Stop Fentanyl Act, H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021; Issues related to the development, manufacture, and distribution of coronavirus vaccines; H.R.4350/S.2792 - National Defense Authorization Act for Fiscal Year 2022 - provisions related to biological and chemical defense and access to naloxone.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on July 17, 2021.
Original Filing: 301278787.xml
Lobbying Issues
National Defense Authorization Act (NDAA) for FY22, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Emergent Biosolutions , earning $60,000. The report was filed on April 19, 2021.
Original Filing: 301259552.xml
Lobbying Issues
National Defense Authorization Act (NDAA) for FY22, provisions related to biological and chemical defense and access to naloxone; S. 4231 (116th Congress) - Preparing for the Next Pandemic Act; Issues regarding opioid and heroin addiction legislation, naloxone access and awareness, and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues regarding State Opioid Response Grant funding; Issues regarding Substance Abuse and Mental Health Block Grant funding; S. 987 - Comprehensive Addiction and Recovery Act (CARA) 3.0; H.R. 2379 -State Opioid Response Grant Authorization Act of 2021; Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder, including S. 166/H.R. 706 - Emergency Support for Substance Use Disorders Act; Issues regarding FY22 appropriations.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Emergent Biosolutions , earning $50,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238196.xml
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to H.R. 133 Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020; Issues related to H.R. 133 Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to H.R. 925 - The Heroes Act; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020; Issues related to H.R. 133 Consolidated Appropriations Act, 2021.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Emergent Biosolutions , earning $40,000. The report was filed on Oct. 19, 2020.
Original Filing: 301215959.xml
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security/Emergencies
Lobbying Issues
Issues related to H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Issues related to FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021; Issues related to H.R. 925 - The Heroes Act; Issues related to S. 4231 - Preparing for the Next Pandemic Act; Issues related to S. 1624 - HEALS Act; Issues related to H.R. 2466 - The State Opioid Response Grant Authorization Act; Issues related to H.R. 7574 - Strengthening Americas Strategic National Stockpile Act of 2020.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Emergent Biosolutions , earning $40,000. The report was filed on July 18, 2020.
Original Filing: 301193308.xml
Lobbying Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Public Law 116-123), H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Public Law 116-123), H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines; Emergency Support for Substance Use Disorders Act/Legislation to create emergency grants for states and community-based organizations that serve individuals with substance use disorder; Health and Economic Recovery Omnibus Emergency Solutions Act (HEROES Act), FY 2021 and Covid-19 next supplemental provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Issues related to State Opioid Response Grants funding for FY 2021.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security/Emergencies/Appropriations
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Emergent Biosolutions , earning $40,000. The report was filed on April 19, 2020.
Original Filing: 301172260.xml
Lobbying Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Public Law 116-123), H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Public Law 116-123), H.R. 748 - CARES Act (Public Law 116-136), and FY 2021 Appropriations related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; NDAA, provisions related to biological and chemical defense; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, naloxone access, co-prescribing, and opioid prescribing guidelines.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Homeland Security/Emergencies/Appropriations
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Emergent Biosolutions , earning $40,000. The report was filed on Jan. 19, 2020.
Original Filing: 301121683.xml
Lobbying Issues
FY 2020 Appropriations - Provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Reauthorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense; H.R. 2968/S. 2474 - Department of Defense Appropriations re Medical Countermeasures; FDA regulatory issues; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, Naloxone access, and co-prescribing/opioid prescribing guidelines; Issues related to FY 2020 Appropriations including: H.R. 3052/S. 2580 - Department of Interior, Environment, and Related Agencies Appropriations Act, 2020; H.R. 2740 - Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020; H.R. 3164/S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Emergent Biosolutions , earning $50,000. The report was filed on Oct. 19, 2019.
Original Filing: 301072294.xml
Lobbying Issues
FY 2020 Appropriations - Provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Reauthorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense; H.R. 2968/S. 2474 - Department of Defense Appropriations re Medical Countermeasures; FDA regulatory issues; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, Naloxone access, and co-prescribing/opioid prescribing guidelines; Issues related to FY 2020 Appropriations including: H.R. 3052/S. 2580 - Department of Interior, Environment, and Related Agencies Appropriations Act, 2020; H.R. 2740 - Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020; H.R. 3164/S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Emergent Biosolutions , earning $50,000. The report was filed on July 19, 2019.
Original Filing: 301052326.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Re-authorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense; Department of Defense appropriations for Medical Countermeasures; FDA regulatory issues; Issues related to Priority Review Voucher programs; Issues regarding opioid and heroin addiction legislation, Naloxone access, and co-prescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Emergent Biosolutions , earning $40,000. The report was filed on April 22, 2019.
Original Filing: 301034643.xml
Lobbying Issues
FY 2020 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government; Re-authorization of the Pandemic and All-Hazards Preparedness Act; NDAA - provisions related to biological and chemical defense; Department of Defense appropriations for Medical Countermeasures; FDA regulatory issues; Issues related to Priority Review Voucher programs; Opioid and heroin addiction legislation, Naloxone access, co-prescribing/opioid prescribing guidelines.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...